Gnathobdellin
Salivary protein family from Asian medicinal leeches Hirudo nipponia and Hirudo japonica — putative anticoagulant.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Salivary protein family from Asian medicinal leeches Hirudo nipponia and Hirudo japonica — putative anticoagulant.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Gnathobdellin is documented at the transcriptomic/sequence level only. No FDA-approved derivative exists, and clinical efficacy is not established.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 10,000 Da
- Source species
- Hirudo nipponia / Hirudo japonica
- Discovered
- 2020
Biological Targets
- → coagulation cascade (mechanism under characterization)
Key Citations
- Lu Z et al. (2018), PLoS One · PMID 30339694
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.